Search Results for "Vytorin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Vytorin. Results 1 to 3 of 3 total matches.

Inclisiran (Leqvio) for LDL-Cholesterol Lowering

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
. 4. Also available in combination with simvastatin (Vytorin, and generics) and rosuvastatin (Roszet ...
The FDA has approved inclisiran (Leqvio – Novartis), a small interfering RNA (siRNA) directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA, as an adjunct to diet and maximally tolerated statin therapy for subcutaneous (SC) treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Inclisiran is the first FDA-approved PCSK9-directed siRNA therapeutic agent.
Med Lett Drugs Ther. 2022 Mar 21;64(1646):43-5 |  Show IntroductionHide Introduction

Comparison Table: Some Lipid-Lowering Drugs (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
35.00 35.00 Ezetimibe/simvastatin – generic Vytorin (Organon) 10/10, 10/20, 10/40, 10/80 mg tabs ...
View the Comparison Table: Some Lipid-Lowering Drugs
Med Lett Drugs Ther. 2022 Sep 19;64(1659):e152-6 |  Show IntroductionHide Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
/simvastatin – generic 10/10, 10/20, 10/40, Initial: 10/10-10/20 mg PO once/day13 40-50% 69.40 Vytorin ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction